Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
21.73 (1y: +133%)
Market Cap 530.12 M P/E(ttm)
Enterprise Value 473.97 M P/B 14.30
CSII- NAS (USA)
Cardiovascular Systems, Inc.
Not Rated
Top Ranked Predictable Companies
$21.73
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 2.028
CSII's Cash to Debt is ranked higher than
63% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. CSII: 2.028 )
CSII' s 10-Year Cash to Debt Range
Min: 1.05   Max: No Debt
Current: 2.03
Equity to Asset 0.51
CSII's Equity to Asset is ranked higher than
57% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. CSII: 0.51 )
CSII' s 10-Year Equity to Asset Range
Min: -1.4   Max: 0.87
Current: 0.51
-1.4
0.87
F-Score: 4
Z-Score: 9.45
M-Score: -2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) -17.50
CSII's Operating margin (%) is ranked higher than
53% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. CSII: -17.50 )
CSII' s 10-Year Operating margin (%) Range
Min: -7725.2   Max: 3.8
Current: -17.5
-7725.2
3.8
Net-margin (%) -20.4
CSII's Net-margin (%) is ranked higher than
54% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. CSII: -20.4 )
CSII' s 10-Year Net-margin (%) Range
Min: -7634.7   Max: 13.1
Current: -20.4
-7634.7
13.1
ROE (%) -52.2
CSII's ROE (%) is ranked higher than
53% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. CSII: -52.2 )
CSII' s 10-Year ROE (%) Range
Min: -134.9   Max: 9.3
Current: -52.2
-134.9
9.3
ROA (%) -26.6
CSII's ROA (%) is ranked higher than
54% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. CSII: -26.6 )
CSII' s 10-Year ROA (%) Range
Min: -64   Max: 8.1
Current: -26.6
-64
8.1
ROC (Joel Greenblatt) (%) -128.80
CSII's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. CSII: -128.80 )
CSII' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1221.3   Max: -81
Current: -128.8
-1221.3
-81
Revenue Growth (%) -10.1
CSII's Revenue Growth (%) is ranked higher than
62% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CSII: -10.1 )
CSII' s 10-Year Revenue Growth (%) Range
Min: -30.5   Max: 17.5
Current: -10.1
-30.5
17.5
EBITDA Growth (%) -34.9
CSII's EBITDA Growth (%) is ranked higher than
66% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CSII: -34.9 )
CSII' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -34.9
Current: -34.9
EPS Growth (%) -4.8
CSII's EPS Growth (%) is ranked higher than
85% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CSII: -4.8 )
CSII' s 10-Year EPS Growth (%) Range
Min: -76.8   Max: -4.8
Current: -4.8
-76.8
-4.8
» CSII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CSII Guru Trades in Q2 2012

Jim Simons 16,800 sh (-21.86%)
» More
Q3 2012

CSII Guru Trades in Q3 2012

Jim Simons 19,000 sh (+13.1%)
» More
Q4 2012

CSII Guru Trades in Q4 2012

Jim Simons 35,300 sh (+85.79%)
» More
Q1 2013

CSII Guru Trades in Q1 2013

Steven Cohen 14,935 sh (New)
Jim Simons 62,800 sh (+77.9%)
» More
» Details

Insider Trades

Latest Guru Trades with CSII

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2012-03-31 Sold Out 0.01%$8.6 - $10.45 $ 21.73149%0
Lee Ainslie 2011-12-31 Reduce -62.32%0.02%$7.41 - $10.3 $ 21.73139%60947
Lee Ainslie 2011-09-30 New Buy0.03%$11.57 - $16.1 $ 21.7357%161747
Lee Ainslie 2011-06-30 Sold Out 0.16%$10.59 - $15.43 $ 21.7370%0
George Soros 2011-06-30 Sold Out $10.59 - $15.43 $ 21.7370%0
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/B 14.30
CSII's P/B is ranked lower than
68% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CSII: 14.30 )
CSII' s 10-Year P/B Range
Min: 0.12   Max: 14.7
Current: 14.3
0.12
14.7
P/S 4.60
CSII's P/S is ranked lower than
54% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CSII: 4.60 )
CSII' s 10-Year P/S Range
Min: 0.19   Max: 6.81
Current: 4.6
0.19
6.81
EV-to-EBIT 4.5
CSII's EV-to-EBIT is ranked higher than
93% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 18.50 vs. CSII: 4.5 )
CSII' s 10-Year EV-to-EBIT Range
Min: 0.4   Max: 6.5
Current: 4.5
0.4
6.5

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 103.5
CSII's Price/Net Cash is ranked lower than
71% of the 90 Companies
in the Global Medical Devices industry.

( Industry Median: 10.50 vs. CSII: 103.5 )
CSII' s 10-Year Price/Net Cash Range
Min: 1.1   Max: 39.2
Current: 103.5
1.1
39.2
Price/Net Current Asset Value 32.4
CSII's Price/Net Current Asset Value is ranked lower than
52% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. CSII: 32.4 )
CSII' s 10-Year Price/Net Current Asset Value Range
Min: 1.7   Max: 18.4
Current: 32.4
1.7
18.4
Price/Tangible Book 15.5
CSII's Price/Tangible Book is ranked lower than
64% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. CSII: 15.5 )
CSII' s 10-Year Price/Tangible Book Range
Min: 1   Max: 12
Current: 15.5
1
12
Price/Median PS Value 2.3
CSII's Price/Median PS Value is ranked lower than
68% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. CSII: 2.3 )
CSII' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 1.7
Current: 2.3
0.5
1.7
Earnings Yield (Greenblatt) 22.40
CSII's Earnings Yield (Greenblatt) is ranked higher than
97% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. CSII: 22.40 )
CSII' s 10-Year Earnings Yield (Greenblatt) Range
Min: 15.4   Max: 258.9
Current: 22.4
15.4
258.9
Forward Rate of Return (Yacktman) 180.4
CSII's Forward Rate of Return (Yacktman) is ranked higher than
100% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CSII: 180.4 )
CSII' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 41.8   Max: 4506.5
Current: 180.4
41.8
4506.5

Business Description

Cardiovascular Systems, Inc. was incorporated as Replidyne, Inc. in Delaware in 2000. On February 25, 2009, Replidyne, Inc. completed its business combination with Cardiovascular Systems, Inc., a Minnesota Corporation. At the effective time of the merger, Replidyne changed its name to Cardiovascular Systems, Inc. CSI is a medical device company focused on developing and commercializing minimally invasive treatment solutions for vascular disease. Interventional endovascular treatment of peripheral artery disease, or PAD, was the initial area of focus. PAD is caused by the accumulation of plaque in peripheral arteries, most commonly occurring in the pelvis and legs, and affects approximately eight to 12 million people in the United States. Its initial product, the Diamondback 360(r) PAD System, is a catheter-based platform capable of treating a range of plaque types in leg arteries both above and below the knee and addresses many of the limitations associated with existing treatment alternatives. The Diamondback 360°'s single-use catheter incorporates a flexible drive shaft with an offset crown coated with diamond grit. With the aid of fluoroscopy, the physician positions the crown at a plaque-containing lesion in the peripheral artery and removes the plaque by causing the crown to orbit against it. This mechanism of action creates a smooth lumen, or channel, in the vessel. The Diamondback 360° is designed to differentiate between plaque and compliant arterial tissue, a concept known as 'differential sanding'. The Diamondback 360° sands plaque into small particles and restores both blood flow and vessel compliance. The particles created by the Diamondback 360° are generally smaller than red blood cells and are carried away by the bloodstream. The small size of the particles avoids the need for plaque collection reservoirs. The Diamondback 360° could treat the diseased arteries with less than three minutes of sanding time, potentially reducing the overall procedure time. In addition to the Diamondback 360°, the Company is expanding its product portfolio through internal product development and establishment of business relationships. CSI now offers multiple accessory devices designed to complement the use of the Diamondback 360°, and have entered into distribution agreements with Invatec, Inc. and Asahi-Intecc, Ltd. CSI markets and sells the Diamondback 360° through a direct sales force in the United States. The Company target its marketing efforts to practitioners through physician education, medical conferences, seminars, peer reviewed journals and marketing materials. The medical device industry is highly competitive, subject to rapid change and is affected by new product introductions and other activities of industry participants. The competitors in the stent and balloon angioplasty market segments include Abbott Laboratories, Boston Scientific, Cook, Johnson & Johnson and Medtronic. The Company also compete against manu
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:R7Y1.Germany
» More Articles for CSII

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Google Inc, Infromatica Corp, Deckers Outdoor Corp and Cardiovascular Sy Aug 14 2011 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 13,170 Shares Nov 19 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 39,330 Shares Nov 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Nov 12 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) CFO Laurence L Betterley sells 5,663 Shares May 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) May 14 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Feb 12 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Nov 16 2009 
CARDIOVASCULAR SYSTEMS, INC. (CSII) CFO Laurence L Betterley buys 7,500 Shares Nov 06 2009 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-K/A) Oct 28 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK